It has been reported that the production of the first mRNA vaccine developed against Kovid-19 in China will start in October. The ARCoV mRNA vaccine, developed jointly by the Chinese People's Liberation Army Military Sciences Academy and Suzhou Abogen Biosciences and Walvax Biotechnology, will be produced at the factory in Yuxi city of Yunnan province in the southwest of the country. It is predicted that the annual production capacity of the factory will be 200 million doses.
The ARCoV vaccine has the same advanced technology as the Pfizer-BioNTech and Moderna vaccines. Pfizer-BioNTech and Moderna vaccines, whose efficacy rates reached 95 percent, surpassed all approved Kovid-19 vaccines with these features.
Ying Bo, founder of Suzhou Abogen Biosciences, pointed out that the results of the first and second phase clinical trials of the ARCoV vaccine in China show that this vaccine is fully competitive with the other two mRNA vaccines.
In a recent statement by Walvax Biotechnology, it was noted that the third phase clinical trials of the vaccine have now been approved in Mexico and Indonesia, and the effectiveness of the vaccine against the Delta variant will also be tested in the trials.
The production capacity is expected to increase rapidly, as the raw materials and key production equipment required for the production of the ARCoV vaccine have been developed in China. The ARCoV vaccine can be stored for more than a week at room temperature and longer at 4 degrees Celsius. This means that the storage and transportation costs of the vaccine will be relatively lower.
Source: China International Radio